Sep 2, 2021Analysts upgrade forecast for immunooncology companyAgenus on the Move Analysts have just delivered a major upgrade to the near-term forecasts for Lexington, Massachusetts-based Agenus, Inc., reported Simply Wall Street. Consensus numbers for revenue and earnings per share (EPS) increased, with the analysts’ views much more bullish on the company’s business prospects. …Oncology4 min readOncology4 min read
Sep 2, 2021Two top FDA vaccine regulators are leavingStepping Down Marion Gruber and Phil Krause, two of the Food and Drug Administration’s top vaccine reviewers, are leaving the agency just as a decision on COVID-19 boosters is imminent. Both intend to step down from the FDA within the next two months. Gruber, who has been with the FDA…FDA3 min readFDA3 min read
Sep 2, 2021FDA finalizes intended use ruleResolution to Confusion The US Food and Drug Administration (FDA) finally finalized a rule that clarifies its position on the types of evidence it will consider when determining the intended use of a medical product. …Clinical Trials3 min readClinical Trials3 min read
Aug 29, 2021Synthetic Biology Hype? Zymergen rallies after Cathie Wood recommendationRoller Coaster Zymergen, which researches, develops and manufactures microbes for industrial application, develops molecules for biomedical coatings and adhesives that can be used as surgical glues inside the body or on the skin to close a wound or to protect against infection. …Zymergen2 min readZymergen2 min read
Aug 29, 2021Jazz Pharmaceuticals drug gets approvalSolving Sleep Disorders The US Food and Drug Administration (FDA) approved Dublin-based Jazz Pharmaceuticals’ Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of idiopathic hypersomnia in adults. Idiopathic hypersomnia is a debilitating neurological sleep disorder characterized by chronic excessive daytime sleepiness, explained Pharma Times. According to…Jazz Pharmaceuticals3 min readJazz Pharmaceuticals3 min read
Aug 29, 2021Lilly forms neuroscience unitShorter Path to Market Eli Lilly & Co. announced on August 17 that it will split its Lilly Bio-Medicines division into two business units: Lilly Neuroscience and Lilly Immunology, effective September 5, reported Tonya Garcia in MarketWatch. …Eli Lilly3 min readEli Lilly3 min read
Aug 29, 2021Personal genomics firm becomes holding company via mergerIs 23 and Me for You? 23andMe, Inc., a publicly held personal genomics and biotechnology company based in Sunnyvale, California, was founded by Linda Avey, Paul Cusenza and Anne Wojcicki in 2006 to provide genetic testing and interpretation to individual consumers. The company is best known for providing a direct-to-consumer…23andme3 min read23andme3 min read
Aug 25, 2021Making Sense of SenseonicsStock rises and falls as FDA approval is pending Senseonics of Germantown, Maryland, produces the Eversense CGM (continuous glucose monitoring) product that it claims is the first implantable device to monitor glucose levels. The market for diabetic care is growing fast. The disease is among the top 10 causes of…Senseonics5 min readSenseonics5 min read
Aug 17, 2021Centessa merges 10 privately held biotechs under one umbrellaNew Model Pharma In February Centessa Pharmaceuticals launched a new kind of pharmaceutical R&D model with $250 million Series A Financing. The company, which was founded by Medicxi, described itself as a merger of 10 privately-held biotech companies with highly validated programs. …Biotechnology5 min readBiotechnology5 min read
Aug 4, 2021Salarius lead candidate is in nine U.S. trial sitesAnswers for Cancer Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focusing on the development of drugs targeting rare, orphan cancers and cancers with a high unmet need, has added Fox Chase Cancer Center Center in Philadelphia to its ongoing trial of seclidemstat as a treatment for Ewing Sarcoma and…Biotech Stock4 min readBiotech Stock4 min read
